Join the debate about IP and innovation in our first Twitter Q&A

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Join the debate about IP and innovation in our first Twitter Q&A

Next week we are trying something new at Managing IP. For the past decade we have published our annual list of the 50 most influential people in IP. This year we are asking the people on it to share their views about the future of IP, and the issues that concern them the most

We will be running these as guest blog posts over the coming weeks and months (you can see the first – Florian Mueller’s views of the Apple-Samsung ex-USA litigation settlement – here).

rosa-wilkinson.jpg

But we also want to engage some of our top 50 in some real-time dialogue about IP issues. So on Tuesday September 23 we will be hosting a Twitter Q&A with Rosa Wilkinson, the UK IPO’s Director of Innovation (pictured).

This is what we said about her in this year’s top 50 list:

“There must be something in the water in Newport, Wales. The twitter account of the UK IPO (which is based in the town) has a whopping 40,000 followers (more than those of the EPO, USPTO and OHIM combined). The Office’s Innovation Director Rosa Wilkinson is a little way behind that figure, but her twitter account is a compelling mix of advice, trivia, links and images, arguing the case for robust IP policy and its role in economic growth.”

We will be asking Rosa about how IP rights can spur innovation (or whether they can hinder it), and whether IP offices offer enough support to SMEs. We will also be asking her about the impact of the Unitary Patent on national IP offices in Europe, and how the UK IPO is preparing for it.

We would like the debate to be as wide as possible, so do join us on the day by following @managingip (it will begin at 4pm BST/11am EST). You can also send us questions in advance, or on the day by emailing mloney@euromoneyplc.com or gnelson@euromoneyplc.com. Remember to use the hashtag #MIP50.

It is also appropriate that our first live Q&A is with a leading woman in IP. This year saw the launch of our Women in IP network, which brings together women (and men) in the profession to share best practices for developing female talent through web seminars, and a series of conferences and breakfast/drinks events. If you want more information about the network please call Melanie Petch on +44 20 7779 8836 or email mpetch@euromoneyplc.com. You can also download the brochure. The network is free to in-house counsel.

more from across site and SHARED ros bottom lb

More from across our site

Not all private equity firms are the same, so leaders at four externally backed IP firms came together to discuss the frameworks they followed and how they ensured a cultural fit
Top-tier German and Spanish firms are among the advisers on a Europe-wide copyright and licensing tussle concerning the design of the track circuit in Madrid
Partners Alex Wilson and Andreas Kramer say bigger law firm rivals don’t necessarily gain by having a wider jurisdictional reach
VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Academic Eden Sarid joins us during Pride Month to discuss queer expression and IP law, Patagonia v Pattie Gonia, and how queer and AI-generated creations both pose novelty concerns
Patent attorney Michael Henson joins the firm to lead its freshly launched blockchain and digital assets practice
A dispute over mammogram technology, and a development in the case between GSK and Moderna were also among the top talking points in recent weeks
Gift this article